2Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patient with chronic epilepsy. Epilepsia, 2000,41:338-341.
3Shank PR, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia, 2000,41: Suppl 1 S3-S9.
4Ben-Menachem E, Henriksen O, Dam M,et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia, 1996,37:539-543.
5Faught E, Wilder BJ, Ramsay RE,et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology, 1996,46:1684-1690.
6Reife R, Pledger G, Wu SC. Topiramate: as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia, 2000,41 Suppl 1 :S66-S71.
7Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: dauble-blind placebo-controlled randomized parallel group trial. Epilepsia, 1999,40 :1767-1774.
